Mitochondria in cutaneous health, disease, ageing and rejuvenation—the 3PM-guided mitochondria-centric dermatology

The EPMA Journal, Год журнала: 2025, Номер unknown

Опубликована: Фев. 14, 2025

Association of both intrinsic and extrinsic risk factors leading to accelerated skin ageing is reflected in excessive ROS production ir/reversible mitochondrial injury burnout, as abundantly demonstrated by accumulating research data. Due the critical role stress pathophysiology disorders, maintained (primary care) restored (secondary health, rejuvenation homoeostasis are considered most effective holistic approach advance dermatological treatments based on systemic health-supportive stimulating measures. Per evidence, an anti-ageing protection, wound healing scarring quality - all strongly depend sustainable functionality well-balanced homoeostasis. The latter can be objectively measured and, if necessary, a manner pre- rehabilitation algorithms tailored individualised patient profiles. entire spectrum corresponding innovations area includes natural rejuvenation, aesthetic reconstructive medicine, protection targeted disorders. Contextually, mitochondria-centric dermatology instrumental for advanced 3PM-guided which makes good use predictive multi-level diagnostics against health-to-disease transition progression relevant Cost-effective new treatment avenues focused health physiologic proposed article including in-depth analysis cases exemplified care with detailed mechanisms expert recommendations presented.

Язык: Английский

---

Characterization of the gut microbiota in drug abuse: prediction, prevention, and personalized medicine to benefit affected populations

The EPMA Journal, Год журнала: 2025, Номер unknown

Опубликована: Март 15, 2025

Язык: Английский

---

Mitochondrial fatty acid oxidation as the target for blocking therapy-resistance and inhibiting tumor recurrence: The proof-of-principle model demonstrated for ovarian cancer cells

Journal of Advanced Research, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Cancer patients treated with current chemotherapeutic and targeted therapies frequently achieve partial remission, which ultimately relapse more aggressive, drug-resistant tumor phenotypes. To a certain extent, drug-tolerant persister (DTP) cells are responsible for residual tumors after systemic anticancer therapy the onset of acquired drug resistance. Therefore, novel targeting DTP to prevent resistance recurrence urgently needed. We aimed investigate traits key vulnerabilities ovarian cancer seek out potential therapeutic strategies. constructed paclitaxel-tolerant by exposing parental lethal dose paclitaxel. Proteomics analysis, in vitro vivo assays were performed identify biological processes that could serve as cells. Paclitaxel-tolerant found undergo metabolic reprogramming through upregulation fatty acid oxidation (FAO). Treatment FAO inhibitor ST1326 suppressed increased sensitivity paclitaxel Moreover, combination prevented satisfactory biosafety mouse model relapse, indicating disruption can improve efficacy paclitaxel-based cancer. Mechanistically, we treatment upregulated CEBPB, transcription factor induced expression FAO-related enzyme HADHA contributed elevation This study revealed an provided prospective paclitaxel-ST1326 may development superior long-term control future. Our research established conceptual framework advancing personalized approaches enhancing patient outcomes therapy.

Язык: Английский

---

Targeting the MAPK signaling pathway: implications and prospects of flavonoids in 3P medicine as modulators of cancer cell plasticity and therapeutic resistance in breast cancer patients

The EPMA Journal, Год журнала: 2025, Номер unknown

Опубликована: Апрель 10, 2025

Abstract Cancer drug resistance poses a significant challenge in oncology, primarily driven by cancer cell plasticity, which promotes tumor initiation, progression, metastasis, and therapeutic evasion many different cancers. Breast cancers (BCs) are prominent example of that, with an estimated 2.3 million new cases 670,000 BC-related deaths registered worldwide annually. Triple-negative BC is especially challenging for treatments demonstrating particularly aggressive disease course, early manifestation metastatic disease, frequent drug-resistant types, poor individual outcomes. Although chemosensitizing agents have been developed, their clinical utility oncology remains unproven. The mitogen-activated protein kinase (MAPK) pathway considered critical regulator intracellular extracellular signaling highly relevant both — genetic epigenetic modifications. Dysregulation the MAPK pathways plays role conferring chemoresistance BC. Contextually, targeting represents promising strategy overcoming enhancing efficacy anticancer treatment. On other hand, flavonoids, class phytochemicals, key modulators signaling. Flavonoids interact ERK, JNK, p38, ERK5 cascade present avenue developing novel anti-cancer therapies re-sensitizing treatment Compounds such as quercetin, kaempferol, genistein, luteolin, myricetin, EGCG, baicalein, baicalin, nobiletin, morin, delphinidin, acacetin, isorhamnetin, apigenin, silymarin, among others, identified specific signaling, exerting complex downstream effects cells increasing therewith suppressing growth aggressivity. These properties reflect mechanisms great relevance to overcome overall management. This article highlights corresponding provides clinically illustrations framework 3P medicine primary (protection individuals at high risk against health-to-disease transition) secondary care progression). 3PM novelty makes good use patient phenotyping stratification, predictive multi-level diagnostics, application Artificial Intelligence (AI) tools individualized interpretation big data all proposed cost-effective tailored profiles clear benefits patients advanced

Язык: Английский

---

Mitochondrial medicine: “from bench to bedside” 3PM-guided concept

The EPMA Journal, Год журнала: 2025, Номер unknown

Опубликована: Апрель 15, 2025

Язык: Английский

---